Back to news

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

Globe Newswire•15/11/2026•18:30 ET
8

Key Highlights

  • ➤Lisaftoclax enters China’s 2026 NRDL for previously treated CLL/SLL patients
  • ➤Olverembatinib renews NRDL coverage for resistant or intolerant CML patients
  • ➤All approved indications for Ascentage Pharma’s two core drugs now have NRDL coverage
  • ➤Updated NRDL coverage takes effect January 1, 2027

Expert Statements

Dajun Yang, Chairman and Chief Executive Officer of Ascentage Pharma

“The successful inclusion of lisaftoclax in the NRDL and the renewal of olverembatinib’s coverage mark that all approved indications of Ascentage Pharma’s two core assets are now covered by the NRDL. For patients, it means greater access to innovative treatment options; for the company, it provides a solid basis for commercialization and sustained innovation; and for the industry, it demonstrates that China’s national reimbursement system supports domestically developed innovative drugs and further recognizes their value, boosting confidence across the pharmaceutical industry to continuously advance original innovation.”

ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that its two core assets are covered by China's 2026 National Reimbursement Drug List (NRDL), providing more patients with greater access to innovative treatment options. Specifically: * Lisaftoclax has been included in the 2026 NRDL for the first time for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. * Olverembatinib has successfully renewed its NRDL coverage through renegotiation for the treatment of (1) adult patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs); and (2) adult patients with CML-CP or accelerated phase (CML-AP) harboring the T315I mutation. With these developments, all approved indications for both of Ascentage Pharma's novel drugs are now covered by the NRDL. The updated NRDL will officially take effect on January 1, 2027.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in